Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8138801
Reference Type
Journal Article
Subtype
Review
Title
MitoQ--a mitochondria-targeted antioxidant
Author(s)
Tauskela, JS
Year
2007
Is Peer Reviewed?
No
Journal
I Drugs: the Investigational Drugs Journal
ISSN:
1369-7056
Volume
10
Issue
6
Page Numbers
399-412
Language
English
PMID
17642004
URL
https://www.ncbi.nlm.nih.gov/pubmed/17642004
Exit
Abstract
MitoQ is an orally active antioxidant that has the ability to target mitochondrial dysfunction. The agent is currently under development by Antipodean Pharmaceuticals Inc in phase II clinical trials for Parkinson's disease and liver damage associated with HCV infection. MitoQ has demonstrated encouraging preclinical results in numerous studies in isolated mitochondria, cells and tissues undergoing oxidative stress and apoptotic death. MitoQ aims to not only mimic the role of the endogenous mitochondrial antioxidant coenzyme Q10 (CoQ10), but also to augment substantially the antioxidant capacity of CoQ to supraphysiological levels in a mitochondrial membrane potential-dependent manner. MitoQ represents the first foray into the clinic in an attempt to deliver an antioxidant to an intracellular region that is responsible for the formation of increased levels of potentially deleterious reactive oxygen species. Results from the clinical trials with MitoQ will have important repercussions on the relevance of a mitochondrial-targeted approach.
Keywords
Alzheimer Disease/prevention & control; Animals; Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/therapeutic; Antioxidants/adverse effects/pharmacology/therapeutic use; Antiparkinson Agents/adverse effects/pharmacology/therapeutic use; Apoptosis/drug effects; Clinical Trials as Topic; Friedreich Ataxia/prevention & control; Hepatitis C/drug therapy; Mitochondria/drug effects/metabolism; Myocardial Reperfusion Injury/prevention & control; Neuroprotective Agents/adverse effects/pharmacology/therapeutic use; Organophosphorus Compounds/adverse effects/pharmacology/therapeutic use; Oxidative Stress/drug effects; Parkinson Disease/drug therapy; Ubiquinone/adverse effects/pharmacology/therapeutic use
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity